Cargando…
Correction: Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757475/ https://www.ncbi.nlm.nih.gov/pubmed/29346800 http://dx.doi.org/10.1136/esmoopen-2017-000235corr1 |
Ejemplares similares
-
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice
por: Sherwood, James L, et al.
Publicado: (2017) -
Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
por: Karlin-Neumann, George
Publicado: (2018) -
Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
por: Sherwood, James
Publicado: (2018) -
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020) -
Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)